title: Dissolution enhancement of Deflazacort using hollow crystals prepared by antisolvent crystallization process.
abstract: Deflazacort (DFZ), a derivate of prednisolone, is a poorly soluble drug which has been proposed to have major advantages over other corticosteroids. Poorly soluble drugs present limited bioavailability due to their low solubility and dissolution rate and several strategies have been developed in order to find ways to improve them. In general, pharmaceutical laboratories use a micronized process to reduce the particle size in order to increase the dissolution of the drugs. However, this process causes changes such as polymorphic transitions, particle agglomeration and a reduction in fluidity and wettability. These solid-state properties affect the dissolution behavior and stability performance of drugs. Crystallization techniques are widely used in the pharmaceutical industry and antisolvent crystallization has been used to obtain ultrafine particles. In this study, DFZ was investigated in terms of its antisolvent crystallization in different solvents and under various preparation conditions (methanol/water ratio, stirring and evaporation rate, etc.), in order to compare the physicochemical properties between crystallized samples and raw materials available on the Brazilian market with and without micronization. Crystalline structure, morphology, and particle size, and their correlation with the Intrinsic Dissolution Rate (IDR) and dissolution profile as relevant biopharmaceutical properties were studied. Crystallization conditions were achieved which provided crystalline samples of hollow-shaped crystals with internal channels, which increased the dissolution rate of DFZ. The antisolvent crystallization process allowed the formation of hollow crystals, which demonstrated a better dissolution profile than the raw material (crystalline and micronized), making this a promising technique as a crystallization strategy for improving the dissolution and thus the bioavailability of poorly soluble drugs.
authors.affiliation: Programa Pós-Graduação em Farmácia, Universidade Federal de Santa Catarina, Florianópolis, Brazil. amarilis_paulino@yahoo.com.br
authors.forename: A S
authors.initials: AS
authors.lastname: Paulino
authors.forename: G
authors.initials: G
authors.lastname: Rauber
authors.forename: C E M
authors.initials: CE
authors.lastname: Campos
authors.forename: M H P
authors.initials: MH
authors.lastname: Maurício
authors.forename: R R
authors.initials: RR
authors.lastname: de Avillez
authors.forename: G
authors.initials: G
authors.lastname: Capobianco
authors.forename: S G
authors.initials: SG
authors.lastname: Cardoso
authors.forename: S L
authors.initials: SL
authors.lastname: Cuffini
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D003460:Crystallization; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D011282:Pregnenediones / Q000737:chemistry*; D012995:Solubility; D014961:X-Ray Diffraction
chemical_list: D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; C021988:deflazacort